IL6 and COVID-19: The unique lipid composition of ProLungTM-budesonide has been shown to have immunomodulating effects, stabilize the endothelium, decrease IL-6 levels, and antiphospholipid antibodies, all of which may play an important role in COVID-19 [9–12].